Atara Biotherapeutics Inc
Buy, Hold or Sell?
Let's analyse Atara Biotherapeutics Inc together
I guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
You can find me behind Let's Analyse Together in the top-right of each section.
Get notifications about Atara Biotherapeutics Inc
I send you an email if I find something interesting about Atara Biotherapeutics Inc.
Quick analysis of Atara Biotherapeutics Inc (30 sec.)
1. Valuation of Atara Biotherapeutics Inc (5 min.)
$1.88
$1.23
2. Growth of Atara Biotherapeutics Inc (5 min.)
Is Atara Biotherapeutics Inc growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | $126.6m | $330m | -$131.1m | -66.0% |
How much money is Atara Biotherapeutics Inc making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$57m | -$85m | $27.9m | ? |
Net Profit Margin | -9,199.0% | -1,796.0% | - | - |
How much money comes from the company's main activities?
3. Financial Health of Atara Biotherapeutics Inc (5 min.)
4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
Fundamentals of Atara Biotherapeutics Inc
Financial Health
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its debts by selling its assets. | ||
The company is able to pay all its debts with equity. |
1.1. Profitability of Atara Biotherapeutics Inc.
1.1. Profitability
1.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- A Net Profit Margin of -33,743.0% means that $-337.43 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -1,796.0%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -2,199.0%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -1,188.6%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -33,743.0% | TTM | -9,199.0% | -24,544.0% | |
TTM | -9,199.0% | YOY | -1,796.0% | -7,403.0% | |
TTM | -9,199.0% | 5Y | -2,199.0% | -7,000.0% | |
5Y | -2,199.0% | 10Y | -1,188.6% | -1,010.4% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -194.7%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -273.6%. trending down. -2
1.1.2. Return on Assets
- Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- -19.8% Return on Assets means that Atara Biotherapeutics Inc generated $-0.20 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -18.0%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -17.5%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -13.5%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -19.8% | TTM | -15.1% | -4.7% | |
TTM | -15.1% | YOY | -18.0% | +2.8% | |
TTM | -15.1% | 5Y | -17.5% | +2.4% | |
5Y | -17.5% | 10Y | -13.5% | -4.0% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -12.4%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -12.5%. trending down. -2
1.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- -58.9% Return on Equity means Atara Biotherapeutics Inc generated $-0.59 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -26.4%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -24.7%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -16.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -58.9% | TTM | -34.0% | -24.9% | |
TTM | -34.0% | YOY | -26.4% | -7.6% | |
TTM | -34.0% | 5Y | -24.7% | -9.3% | |
5Y | -24.7% | 10Y | -16.9% | -7.8% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -15.2%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -15.5%. trending down. -2
1.2. Operating Efficiency of Atara Biotherapeutics Inc.
1.2. Operating Efficiency
1.2.1. Operating Margin
- Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- An Operating Margin of -32,840.3% means the company generated $-328.40 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -1,795.8%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -2,159.5%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -1,167.3%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -32,840.3% | TTM | -9,001.6% | -23,838.6% | |
TTM | -9,001.6% | YOY | -1,795.8% | -7,205.9% | |
TTM | -9,001.6% | 5Y | -2,159.5% | -6,842.2% | |
5Y | -2,159.5% | 10Y | -1,167.3% | -992.2% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -318.9%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -267.4%. trending down. -2
1.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 342.81 means that the operating costs are $342.81 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 18.976. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 22.669. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 12.253. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 342.805 | TTM | 94.367 | +248.438 | |
TTM | 94.367 | YOY | 18.976 | +75.391 | |
TTM | 94.367 | 5Y | 22.669 | +71.698 | |
5Y | 22.669 | 10Y | 12.253 | +10.415 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.013. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 3.644. trending up. -2
1.3. Liquidity of Atara Biotherapeutics Inc.
1.3. Liquidity
1.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 3.74 means the company has $3.74 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 4.464. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 8.004. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 17.113. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 3.739 | TTM | 4.009 | -0.270 | |
TTM | 4.009 | YOY | 4.464 | -0.455 | |
TTM | 4.009 | 5Y | 8.004 | -3.995 | |
5Y | 8.004 | 10Y | 17.113 | -9.109 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 4.559. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 4.993. trending down. -2
1.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- A Quick Ratio of 5.49 means the company can pay off $5.49 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 7.171. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 13.400. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 28.385. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 5.486 | TTM | 6.476 | -0.991 | |
TTM | 6.476 | YOY | 7.171 | -0.694 | |
TTM | 6.476 | 5Y | 13.400 | -6.924 | |
5Y | 13.400 | 10Y | 28.385 | -14.985 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.881. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 4.502. trending up. +2
1.4. Solvency of Atara Biotherapeutics Inc.
1.3. Liquidity
1.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.66 means that Atara Biotherapeutics Inc assets are financed with 66.4% credit (debt) and the remaining percentage (100% - 66.4%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 0.309. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.239. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.255. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.664 | TTM | 0.500 | +0.163 | |
TTM | 0.500 | YOY | 0.309 | +0.192 | |
TTM | 0.500 | 5Y | 0.239 | +0.261 | |
5Y | 0.239 | 10Y | 0.255 | -0.016 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.311. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.298. trending up. -2
1.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- A Debt to Equity ratio of 197.2% means that company has $1.97 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 0.457. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.402. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.240. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.972 | TTM | 1.101 | +0.871 | |
TTM | 1.101 | YOY | 0.457 | +0.644 | |
TTM | 1.101 | 5Y | 0.402 | +0.700 | |
5Y | 0.402 | 10Y | 0.240 | +0.161 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.363. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.362. trending up. -2
2. Market Valuation of Atara Biotherapeutics Inc
2. Earnings Per Share
2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
- A PE ratio of -4.54 means the investor is paying $-4.54 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -18.130. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -25.668. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -64.109. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -2.601 | MRQ | -4.538 | +1.937 | |
MRQ | -4.538 | TTM | 5.802 | -10.341 | |
TTM | 5.802 | YOY | -18.130 | +23.933 | |
TTM | 5.802 | 5Y | -25.668 | +31.470 | |
5Y | -25.668 | 10Y | -64.109 | +38.441 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -7.165. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -8.417. trending up. -2
2.2. Price Earnings to Growth Ratio
- Lower is better.
- A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.
Let's take a look of the Price Earnings to Growth Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is -18.789. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -30.373. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -98.630. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -4.053 | TTM | 1.666 | -5.719 | |
TTM | 1.666 | YOY | -18.789 | +20.455 | |
TTM | 1.666 | 5Y | -30.373 | +32.039 | |
5Y | -30.373 | 10Y | -98.630 | +68.257 |
Compared to industry (Biotechnology)
Let compare the company's Price Earnings to Growth Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -4.287. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -6.137. trending up. -2
2. Book Value per Share
2.3. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 2.67 means the investor is paying $2.67 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:
Trends
- The YOY is 4.769. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 5.678. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 7.378. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 1.532 | MRQ | 2.672 | -1.141 | |
MRQ | 2.672 | TTM | 2.999 | -0.326 | |
TTM | 2.999 | YOY | 4.769 | -1.770 | |
TTM | 2.999 | 5Y | 5.678 | -2.679 | |
5Y | 5.678 | 10Y | 7.378 | -1.700 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.024. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.335. trending up. -2
2. Total Gains per Share
3. Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.
3.1. Institutions holding Atara Biotherapeutics Inc
Institutions are holding 103.982% of the shares of Atara Biotherapeutics Inc.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2022-12-31 | BlackRock Inc | 9.5219 | 0.0009 | 9152149 | 240158 | 2.6948 |
2022-12-31 | Wasatch Advisors Inc. | 8.73 | 0.1853 | 8391014 | 254651 | 3.1298 |
2022-12-31 | Baupost Group LLC | 8.4518 | 0.4346 | 8123616 | 0 | 0 |
2022-12-31 | State Street Corporation | 7.9588 | 0.0015 | 7649740 | -447613 | -5.5279 |
2022-12-31 | JPMorgan Chase & Co | 7.8024 | 0.0032 | 7499435 | -783953 | -9.4642 |
2022-12-31 | Vanguard Group Inc | 7.5023 | 0.0006 | 7211048 | 604539 | 9.1507 |
2022-12-31 | Maverick Capital Ltd | 6.5451 | 0.4886 | 6291013 | -1564811 | -19.9191 |
2022-12-31 | Goldman Sachs Group Inc | 6.4958 | 0.0046 | 6243613 | 1484933 | 31.2047 |
2022-12-31 | Redmile Group, LLC | 6.4949 | 0.8376 | 6242756 | 0 | 0 |
2022-12-31 | D. E. Shaw & Co LP | 3.6747 | 0.0128 | 3532000 | 812100 | 29.8577 |
2022-12-31 | Morgan Stanley - Brokerage Accounts | 2.7984 | 0.001 | 2689744 | -259172 | -8.7887 |
2022-09-30 | KPCB XV Associates LLC | 1.9525 | 19.7946 | 1876650 | 0 | 0 |
2022-12-31 | Geode Capital Management, LLC | 1.9181 | 0.0009 | 1843618 | 72294 | 4.0814 |
2022-12-31 | Citadel Advisors Llc | 1.4542 | 0.0011 | 1397765 | 1366179 | 4325.2675 |
2022-12-31 | Ameriprise Financial Inc | 1.3873 | 0.0015 | 1333420 | 460844 | 52.8142 |
2022-12-31 | Nuveen Asset Management, LLC | 1.3263 | 0.0016 | 1274847 | 752345 | 143.9889 |
2022-12-31 | Citigroup Inc | 1.0668 | 0.0027 | 1025418 | -264213 | -20.4875 |
2022-12-31 | Antipodean Advisors LLC | 1.0404 | 10.9516 | 1000000 | 0 | 0 |
2022-12-31 | Jacobs Levy Equity Management, Inc. | 1.0022 | 0.0214 | 963272 | 607947 | 171.096 |
2022-12-31 | Dimensional Fund Advisors, Inc. | 0.924 | 0.0009 | 888165 | 271197 | 43.9564 |
Total | 88.0479 | 32.747 | 84629283 | +3607425 | +4.3% |
3.2. Funds holding Atara Biotherapeutics Inc
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2023-03-31 | SPDR® S&P Biotech ETF | 5.4144 | 0.2344 | 5204123 | -60567 | -1.1504 |
2022-12-31 | Vanguard Instl Ttl Stck Mkt Idx Tr | 2.8197 | 0.0008 | 2710236 | 367196 | 15.6718 |
2023-03-31 | Vanguard Total Stock Mkt Idx Inv | 2.8197 | 0.0006 | 2710236 | 0 | 0 |
2023-02-28 | JPMorgan Small Cap Growth A | 2.5262 | 0.2469 | 2428081 | 0 | 0 |
2022-12-31 | Wasatch Small Cap Growth Investor | 2.4675 | 0.3933 | 2371687 | -70450 | -2.8848 |
2023-03-31 | JPM Global Healthcare C (acc) USD | 2.3297 | 0.1352 | 2239196 | 0 | 0 |
2023-03-31 | iShares Russell 2000 ETF | 2.0958 | 0.0118 | 2014393 | -22806 | -1.1195 |
2022-12-31 | Wasatch Ultra Growth | 1.958 | 0.4708 | 1881974 | -20204 | -1.0622 |
2022-12-31 | Wasatch Small Cap Value | 1.4288 | 0.3366 | 1373334 | 0 | 0 |
2023-03-31 | Vanguard Extended Market Index Investor | 1.4128 | 0.0046 | 1357911 | 27092 | 2.0357 |
2023-01-31 | Vanguard Explorer Inv | 1.1578 | 0.0277 | 1112882 | 0 | 0 |
2023-03-31 | iShares Russell 2000 Value ETF | 0.9336 | 0.0227 | 897346 | 3228 | 0.361 |
2023-03-31 | State St Russell Sm/Mid Cp® Indx NL Cl C | 0.8877 | 0.0078 | 853277 | 0 | 0 |
2023-03-31 | JPM Thematics Genetic Thrps C2 Acc USD | 0.84 | 0.2439 | 807374 | 0 | 0 |
2023-01-31 | Fidelity® Small Cap Index | 0.804 | 0.0188 | 772782 | 16521 | 2.1846 |
2023-02-28 | CREF Stock R1 | 0.754 | 0.0027 | 724681 | 89040 | 14.0079 |
2023-03-31 | Columbia Small Cap Value I | 0.7487 | 0.155 | 719670 | 23000 | 3.3014 |
2023-03-31 | Columbia Small Cap Value I A | 0.7487 | 0.1551 | 719670 | 6500 | 0.9114 |
2023-03-31 | iShares Biotechnology ETF | 0.7422 | 0.0258 | 713350 | -574 | -0.0804 |
2023-03-31 | Xtrackers S&P Global Infras Swap ETF 1C | 0.6761 | 0.6324 | 649808 | 649808 | 0 |
Total | 33.5654 | 3.1269 | 32262011 | +1007784 | +3.1% |
3.3. Insider Transactions
Insiders are holding 1.626% of the shares of Atara Biotherapeutics Inc.
4. Summary
4.1. Key Performance Indicators
The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -0.599 | -0.411 | -31% | -0.479 | -20% | -0.031 | -95% | 0.033 | -1907% |
Book Value Growth | - | - | 0.677 | 0.838 | -19% | 0.883 | -23% | 1.033 | -35% | 1.288 | -47% |
Book Value Per Share | - | - | 1.227 | 1.952 | -37% | 3.410 | -64% | 3.251 | -62% | 2.605 | -53% |
Book Value Per Share Growth | - | - | 0.672 | 0.826 | -19% | 0.881 | -24% | 1.031 | -35% | 1.286 | -48% |
Current Ratio | - | - | 3.739 | 4.009 | -7% | 4.464 | -16% | 8.004 | -53% | 17.113 | -78% |
Debt To Asset Ratio | - | - | 0.664 | 0.500 | +33% | 0.309 | +115% | 0.239 | +178% | 0.255 | +160% |
Debt To Equity Ratio | - | - | 1.972 | 1.101 | +79% | 0.457 | +331% | 0.402 | +391% | 0.240 | +721% |
Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Eps | - | - | -0.723 | -0.559 | -23% | -0.878 | +21% | -0.716 | -1% | -0.472 | -35% |
Eps Growth | - | - | 1.120 | -0.029 | +103% | 0.966 | +16% | 0.739 | +52% | 0.690 | +62% |
Free Cash Flow Per Share | - | - | -0.552 | -0.674 | +22% | -0.597 | +8% | -0.587 | +6% | -0.381 | -31% |
Free Cash Flow Per Share Growth | - | - | 1.133 | 0.776 | +46% | -2.222 | +296% | 0.324 | +250% | 0.420 | +170% |
Free Cash Flow To Equity Per Share | - | - | -0.239 | -0.544 | +128% | -0.329 | +38% | -0.003 | -99% | 0.043 | -650% |
Free Cash Flow To Equity Per Share Growth | - | - | 1.626 | -0.187 | +111% | 1.340 | +21% | 1.515 | +7% | 2.015 | -19% |
Gross Profit Margin | - | - | 1.000 | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% | 1.000 | 0% |
Intrinsic Value_10Y_max | - | - | 13.619 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -24.088 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -1.801 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -2.664 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -2.998 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -7.836 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -1.287 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -12.781 | - | - | - | - | - | - | - | - |
Net Profit Margin | - | - | -337.430 | -91.990 | -73% | -17.960 | -95% | -21.990 | -93% | -11.886 | -96% |
Operating Margin | - | - | -328.403 | -90.016 | -73% | -17.958 | -95% | -21.595 | -93% | -11.673 | -96% |
Operating Ratio | - | - | 342.805 | 94.367 | +263% | 18.976 | +1707% | 22.669 | +1412% | 12.253 | +2698% |
Pb Ratio | 1.532 | -74% | 2.672 | 2.999 | -11% | 4.769 | -44% | 5.678 | -53% | 7.378 | -64% |
Pe Ratio | -2.601 | +43% | -4.538 | 5.802 | -178% | -18.130 | +299% | -25.668 | +466% | -64.109 | +1313% |
Peg Ratio | - | - | -4.053 | 1.666 | -343% | -18.789 | +364% | -30.373 | +649% | -98.630 | +2333% |
Price Per Share | 1.880 | -74% | 3.280 | 6.035 | -46% | 15.893 | -79% | 19.284 | -83% | 19.214 | -83% |
Price To Total Gains Ratio | -3.136 | +43% | -5.471 | 0.153 | -3679% | -42.875 | +684% | -10.569 | +93% | -43.536 | +696% |
Profit Growth | - | - | 1.113 | -0.043 | +104% | 0.963 | +16% | 0.735 | +51% | 0.755 | +47% |
Quick Ratio | - | - | 5.486 | 6.476 | -15% | 7.171 | -23% | 13.400 | -59% | 28.385 | -81% |
Return On Assets | - | - | -0.198 | -0.151 | -24% | -0.180 | -9% | -0.175 | -12% | -0.135 | -32% |
Return On Equity | - | - | -0.589 | -0.340 | -42% | -0.264 | -55% | -0.247 | -58% | -0.169 | -71% |
Revenue Growth | - | - | 0.050 | 2.039 | -98% | 1.294 | -96% | 1.720 | -97% | 1.720 | -97% |
Total Gains Per Share | - | - | -0.599 | -0.411 | -31% | -0.479 | -20% | -0.031 | -95% | 0.033 | -1907% |
Total Gains Per Share Growth | - | - | 1.145 | 0.346 | +231% | 0.625 | +83% | 1.478 | -23% | 2.082 | -45% |
Usd Book Value | - | - | 126640000.000 | 198887000.000 | -36% | 330082500.000 | -62% | 316256450.000 | -60% | 252867459.459 | -50% |
Usd Book Value Change Per Share | - | - | -0.599 | -0.411 | -31% | -0.479 | -20% | -0.031 | -95% | 0.033 | -1907% |
Usd Book Value Per Share | - | - | 1.227 | 1.952 | -37% | 3.410 | -64% | 3.251 | -62% | 2.605 | -53% |
Usd Dividend Per Share | - | - | - | - | 0% | - | 0% | - | 0% | - | 0% |
Usd Eps | - | - | -0.723 | -0.559 | -23% | -0.878 | +21% | -0.716 | -1% | -0.472 | -35% |
Usd Free Cash Flow | - | - | -56917000.000 | -68655750.000 | +21% | -57775500.000 | +2% | -57402650.000 | +1% | -37174081.081 | -35% |
Usd Free Cash Flow Per Share | - | - | -0.552 | -0.674 | +22% | -0.597 | +8% | -0.587 | +6% | -0.381 | -31% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.239 | -0.544 | +128% | -0.329 | +38% | -0.003 | -99% | 0.043 | -650% |
Usd Price Per Share | 1.880 | -74% | 3.280 | 6.035 | -46% | 15.893 | -79% | 19.284 | -83% | 19.214 | -83% |
Usd Profit | - | - | -74572000.000 | -57046750.000 | -24% | -85035250.000 | +14% | -69831150.000 | -6% | -45512054.054 | -39% |
Usd Revenue | - | - | 221000.000 | 15893250.000 | -99% | 5085000.000 | -96% | 4195650.000 | -95% | 2267918.919 | -90% |
Usd Total Gains Per Share | - | - | -0.599 | -0.411 | -31% | -0.479 | -20% | -0.031 | -95% | 0.033 | -1907% |
EOD | +3 -2 | MRQ | TTM | +14 -25 | YOY | +16 -23 | 5Y | +10 -29 | 10Y | +6 -33 |
4.2. Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -2.601 | |
Price to Book Ratio (EOD) | Between | 0-1 | 1.532 | |
Net Profit Margin (MRQ) | Greater than | 0 | -337.430 | |
Operating Margin (MRQ) | Greater than | 0 | -328.403 | |
Quick Ratio (MRQ) | Greater than | 1 | 5.486 | |
Current Ratio (MRQ) | Greater than | 1 | 3.739 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.664 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 1.972 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.589 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.198 | |
Total | 3/10 (30.0%) |
4.3. Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Open | Greater than | Close | 1.640 | |
Total | 0/1 (0.0%) |
Latest Balance Sheet
Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 249,780 |
Total Stockholder Equity | + 126,640 |
Total Assets | = 376,420 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 74,322 |
Long-term Assets Other | 7,018 |
Long-term Assets (as reported) | 81,340 |
---|---|
Long-term Assets (calculated) | 81,340 |
+/- | 0 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt | 58,064 |
Long-term Liabilities Other | 170,864 |
Long-term Liabilities (as reported) | 170,864 |
---|---|
Long-term Liabilities (calculated) | 228,928 |
+/- | 58,064 |
Other
Balance Sheet
Currency in USD. All numbers in thousands.
Trend | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 376,420 | 368,316 | 436,121 | 397,280 | 468,127 | 449,923 | 456,791 | 529,637 | 588,120 | 405,532 | 428,111 | 299,547 | 342,942 | 364,785 | 274,144 | 324,726 | 391,839 | 442,940 | 492,707 | 473,108 | 217,779 | 229,693 | 244,155 | 241,738 | 263,914 | 284,417 | 300,814 | 312,978 | 324,975 | 340,379 | 161,102 | 169,817 | 106,122 | 54,120 | 58,503 | 62,866 | 51,828 | 0 | 0 | 0 | 4,290 | |||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 295,080 | 283,046 | 346,984 | 314,389 | 384,621 | 369,497 | 392,325 | 464,307 | 523,273 | 339,432 | 358,987 | 229,217 | 272,992 | 293,418 | 201,139 | 250,830 | 321,489 | 372,976 | 425,070 | 413,614 | 172,190 | 206,217 | 222,492 | 235,318 | 260,553 | 282,230 | 298,883 | 311,741 | 324,597 | 340,235 | 160,634 | 169,691 | 106,026 | 52,022 | 57,085 | 62,291 | 51,808 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 92,942 | 65,114 | 70,688 | 101,669 | 106,084 | 113,209 | 123,856 | 151,097 | 200,404 | 62,620 | 74,511 | 70,203 | 74,317 | 94,431 | 59,159 | 56,168 | 60,698 | 66,028 | 103,203 | 90,495 | 79,223 | 60,493 | 64,237 | 62,430 | 47,968 | 46,013 | 26,356 | 22,056 | 23,746 | 54,466 | 26,190 | 71,329 | 21,897 | 25,703 | 31,779 | 39,754 | 51,615 | 0 | 0 | 0 | 4,207 | |||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 149,877 | 200,290 | 260,623 | 200,142 | 264,984 | 244,036 | 249,524 | 284,064 | 300,255 | 264,565 | 273,201 | 144,428 | 184,792 | 188,491 | 130,976 | 181,377 | 248,933 | 298,515 | 313,812 | 316,826 | 86,873 | 139,728 | 152,659 | 168,216 | 207,714 | 232,134 | 268,201 | 284,347 | 296,736 | 279,799 | 128,841 | 95,367 | 82,219 | 25,996 | 24,719 | 22,277 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 40,221 | 249 | 637 | 668 | 986 | 400 | 700 | 9,610 | 1,250 | 800 | 800 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Inventory |
| 1,586 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 81,340 | 85,270 | 89,137 | 82,891 | 83,506 | 80,426 | 64,466 | 65,330 | 64,847 | 66,100 | 69,124 | 70,330 | 69,950 | 71,367 | 73,005 | 73,896 | 70,350 | 69,964 | 67,637 | 59,494 | 45,589 | 23,476 | 21,663 | 6,420 | 3,361 | 2,187 | 1,931 | 1,237 | 378 | 144 | 468 | 126 | 96 | 2,098 | 1,418 | 575 | 20 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 74,322 | 78,104 | 81,910 | 28,042 | 79,939 | 78,556 | 62,577 | 63,401 | 62,820 | 64,023 | 66,908 | 68,133 | 68,183 | 69,901 | 71,486 | 72,160 | 68,576 | 68,279 | 66,075 | 58,194 | 44,129 | 22,176 | 20,287 | 4,400 | 3,259 | 2,085 | 1,830 | 1,148 | 270 | 46 | 42 | 47 | 48 | 14 | 11 | 8 | 8 | 0 | 0 | 0 | 9 | |||||||||||||||||||||||||||||||||||||||||
Long-term Assets Other |
| 7,018 | 7,166 | 7,227 | 54,849 | 3,567 | 1,870 | 1,889 | 1,929 | 2,027 | 2,077 | 2,216 | 2,197 | 1,767 | 1,466 | 1,519 | 1,736 | 1,774 | 1,685 | 1,562 | 1,300 | 1,460 | 1,300 | 1,376 | 2,020 | 102 | 102 | 101 | 89 | 108 | 98 | 426 | 79 | 48 | 2,084 | 1,407 | 567 | 12 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 249,780 | 181,203 | 178,642 | 172,964 | 188,513 | 139,782 | 125,253 | 130,600 | 125,781 | 51,597 | 46,986 | 46,725 | 52,161 | 46,343 | 41,865 | 40,792 | 52,982 | 39,886 | 40,208 | 33,924 | 39,915 | 23,737 | 23,011 | 8,604 | 10,178 | 14,215 | 10,569 | 9,144 | 9,875 | 6,631 | 11,847 | 3,723 | 2,940 | 77,149 | 2,280 | 77,570 | 62,845 | 0 | 0 | 0 | 1,306 | |||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 78,916 | 72,244 | 65,688 | 101,562 | 105,786 | 86,150 | 88,830 | 84,194 | 82,901 | 36,055 | 31,684 | 31,520 | 36,743 | 30,706 | 25,803 | 25,175 | 39,979 | 27,000 | 27,234 | 21,049 | 27,646 | 16,516 | 11,481 | 7,805 | 9,675 | 13,688 | 10,006 | 8,860 | 9,709 | 6,450 | 11,644 | 3,514 | 2,724 | 2,412 | 2,101 | 2,788 | 1,524 | 0 | 0 | 0 | 1,302 | |||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 13,640 | 0 | 0 | 0 | 2,753 | 0 | 0 | 0 | 1,985 | 0 | 0 | 0 | 1,581 | 0 | 0 | 643 | 0 | 0 | 10,300 | 10,300 | 500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 643 | 0 | 0 | 10,300 | 10,300 | 500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 6,871 | 11,296 | 12,799 | 11,945 | 17,368 | 16,543 | 12,301 | 17,355 | 7,118 | 5,190 | 5,106 | 8,079 | 7,963 | 5,155 | 6,420 | 6,168 | 3,719 | 6,193 | 6,545 | 6,098 | 14,711 | 5,539 | 5,243 | 2,204 | 2,778 | 4,463 | 3,235 | 1,896 | 1,445 | 1,853 | 1,703 | 794 | 440 | 569 | 577 | 1,402 | 606 | 0 | 0 | 0 | 121 | |||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 50,405 | 58,286 | 51,218 | 38,674 | 44,905 | 38,381 | 35,561 | 31,342 | 40,343 | 30,865 | 26,578 | 23,441 | 27,199 | 25,551 | 19,383 | 19,007 | 36,260 | 20,807 | 20,689 | 14,951 | 12,935 | 10,977 | 6,238 | 5,601 | 6,897 | 9,225 | 6,771 | 6,964 | 8,264 | 4,597 | 9,941 | 2,720 | 2,284 | 1,843 | 1,524 | 1,386 | 918 | 0 | 0 | 0 | 1,174 | |||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 170,864 | 108,959 | 112,954 | 71,402 | 82,727 | 53,632 | 36,423 | 46,406 | 42,880 | 15,542 | 15,302 | 15,205 | 15,418 | 15,637 | 16,062 | 15,617 | 13,003 | 12,886 | 12,974 | 12,875 | 12,269 | 7,221 | 11,530 | 799 | 503 | 527 | 563 | 284 | 166 | 181 | 203 | 209 | 216 | 74,737 | 179 | 74,782 | 61,321 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Long term Debt Total |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 244 | 85 | 141 | 196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Capital Lease Obligations Min Short Term Debt |
| 58,064 | 61,072 | 63,999 | 17,453 | 22,765 | 24,574 | 12,182 | 12,569 | 13,041 | 13,129 | 13,420 | 13,809 | 14,136 | 14,532 | 14,919 | 13,794 | 0 | 0 | -10,300 | -10,300 | -500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Warrants |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 149,144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Long-term Liabilities Other |
| 170,864 | 108,959 | 5,626 | 71,402 | 1,501 | 53,632 | 1,771 | 46,406 | 42,880 | 15,542 | 15,302 | 15,205 | 15,418 | 15,637 | 16,062 | 15,617 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 181 | 203 | 209 | 216 | 165 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 126,640 | 187,113 | 257,479 | 224,316 | 279,614 | 310,141 | 331,538 | 399,037 | 462,339 | 353,935 | 381,125 | 252,822 | 290,781 | 318,442 | 232,279 | 283,934 | 338,857 | 403,054 | 452,499 | 439,184 | 177,864 | 205,956 | 221,144 | 233,134 | 253,736 | 270,202 | 290,245 | 303,834 | 315,100 | 333,748 | 149,255 | 166,094 | 103,182 | -23,029 | 56,223 | -14,704 | -11,017 | 0 | 0 | 0 | 2,984 | |||||||||||||||||||||||||||||||||||||||||
Common Stock |
| 10 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | |||||||||||||||||||||||||||||||||||||||||
Retained Earnings Total Equity | -1,693,024 | -1,618,452 | -1,534,361 | -1,552,827 | -1,464,722 | -1,371,373 | -1,286,709 | -1,202,916 | -1,124,581 | -1,043,274 | -968,926 | -891,470 | -817,961 | -739,465 | -667,570 | -593,242 | -527,349 | -447,337 | -388,976 | -338,093 | -296,650 | -261,337 | -230,241 | -202,813 | -177,159 | -158,924 | -133,551 | -114,671 | -98,110 | -76,862 | -64,994 | -50,049 | -40,889 | -30,362 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income |
| -2,067 | -2,959 | -2,618 | -1,892 | -368 | 24 | 62 | 161 | 296 | 527 | 810 | 204 | 220 | 233 | 173 | 38 | -340 | -449 | -505 | -524 | -151 | -88 | -114 | -152 | -183 | 35 | 193 | 51 | -518 | 51 | -66 | -18 | -100 | -11 | 0 | -11 | -3,823 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Capital Surplus |
| 1,821,721 | 1,808,515 | 1,794,449 | 1,779,026 | 1,744,695 | 1,681,481 | 1,618,177 | 1,601,784 | 1,586,616 | 1,396,674 | 1,349,234 | 1,144,082 | 1,108,516 | 1,057,669 | 899,671 | 877,133 | 866,541 | 850,835 | 841,975 | 777,797 | 474,662 | 467,378 | 451,496 | 436,096 | 431,075 | 429,088 | 423,600 | 418,451 | 413,725 | 410,556 | 214,313 | 216,159 | 144,169 | 7,344 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 1,821,721 | 1,808,515 | 1,794,449 | 1,779,026 | 1,744,695 | 1,681,481 | 1,618,177 | 1,601,784 | 1,586,616 | 1,396,674 | 1,349,234 | 1,144,082 | 1,108,516 | 1,057,669 | 899,671 | 877,133 | 866,541 | 850,835 | 841,975 | 777,797 | 474,662 | 467,378 | 451,496 | 436,096 | 431,075 | 429,088 | 423,600 | 418,451 | 413,725 | 410,556 | 214,313 | 216,159 | 144,169 | 7,344 | 84,477 | 5,239 | 1,865 | 0 | 0 | 0 | 0 |
Balance Sheet
Currency in USD. All numbers in thousands.
Cash Flow
Currency in USD. All numbers in thousands.
Income Statement
Currency in USD. All numbers in thousands.
Latest Income Statement (annual, 2022-12-31)
Gross Profit (+$) | ||
---|---|---|
totalRevenue | 63,573 | |
Cost of Revenue | -- | |
Gross Profit | 63,573 | 63,573 |
Operating Income (+$) | ||
Gross Profit | 63,573 | |
Operating Expense | -344,086 | |
Operating Income | -280,513 | -280,513 |
Operating Expense (+$) | ||
Research Development | 272,533 | |
Selling General Administrative | 71,553 | |
Selling And Marketing Expenses | - | |
Operating Expense | 344,086 | 344,086 |
Net Interest Income (+$) | ||
Interest Income | 1,986 | |
Interest Expense | -1,986 | |
Other Finance Cost | -1,986 | |
Net Interest Income | 1,986 | |
Pretax Income (+$) | ||
Operating Income | -280,513 | |
Net Interest Income | 1,986 | |
Other Non-Operating Income Expenses | 52,223 | |
Income Before Tax (EBT) | -228,290 | -332,736 EBIT - interestExpense = -282,499 -228,290 -226,316 |
Interest Expense | 1,986 | |
Earnings Before Interest and Taxes (EBIT) | -280,513 | -226,304 |
Earnings Before Interest and Taxes (EBITDA) | -330,750 | |
After tax Income (+$) | ||
Income Before Tax | -228,290 | |
Tax Provision | -12 | |
Net Income From Continuing Ops | -228,302 | -228,302 |
Net Income | -228,302 | |
Net Income Applicable To Common Shares | -228,302 | |
Non-recurring Events | ||
Discontinued Operations | - | |
Extraordinary Items | - | |
Effect of Accounting Charges | - | |
Other Items | - | |
Non Recurring | - | |
Other Operating Expenses | 344,086 | |
Total Other Income/Expenses Net | 52,223 | -54,209 |
Technicals of Atara Biotherapeutics Inc
1. Trend Indicators
1.1 Moving Averages
- Moving averages are lagging trend indicators.
- There are many types of moving averages.
- Moving averages are also used within other indicators.
Directionalities and relatives.
Moving Average | Amount of candles | Trend | Price +/- | vs. MA 50 | vs. MA 100 | vs. MA 200 |
---|
Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I
1.2 Moving Average Convergence/Divergence (MACD)
- MACD is a lagging momentum indicator.
- Uses two moving averages.
- Can show buy or sell signals based on momentum.
- Can show overbought. and oversold. levels.
Let's take a look of the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc:
1.3 Directional Movement Index (DMI)
The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).
The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Atara Biotherapeutics Inc:
- The ADX is .